MedTrace Logo

Conversion From Parenteral to Oral Methadone.

NCT01836328 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2016-03-16

No results posted yet for this study

Summary

The majority of current studies regarding the use of methadone (MTD) in the treatment of cancer pain are focused in its administration via the oral route (PO). The ratio considered from VO to parenteral route (BP) is 2:1. Academic literature assumes the ratio from BP to VO to be 1:2. In our unit, we use MTD in the context of ROP and not as the last opioid. If face with a situation where there is a good control of pain with MTD BP, usually we move to VO. We have observed that the traditional ratio tend to produce certain toxicity problems. Because of this, we have proposed a new ratio of conversion from PAR MTD to oral MTD, i.e. 1:1.2

Conditions

Interventions

DRUG

Parenteral /oral methadone ratio 1:2

See "arm/group descriptions"

DRUG

Parenteral /oral methadone ratio 1:1.2

See "arm/group descriptions"

Sponsors & Collaborators

  • Hospital Arnau de Vilanova

    collaborator OTHER

  • Hospital Universitario La Paz

    collaborator OTHER

  • L'Hospitalet de Llobregat

    lead OTHER

Principal Investigators

  • JESÚS GONZÁLEZ-BARBOTEO, MD · INSTITUT CATALÀ D'ONCOLOGIA. HOSPITAL DURAN I REYNALS

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01836328 on ClinicalTrials.gov